Schonfeld Strategic Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,340	Closed	-$39K	–	3046
2022 Q3	$39K	Sell	1,340 -1,920	-59%	-$65.8K	﹤0.01%	2665
2022 Q2	$62K	Buy	+3,260	New	+$164K	﹤0.01%	2197
2021 Q2	–	Sell	-4,431	Closed	-$672K	–	2340
2021 Q1	$672K	Buy	+4,431	New	+$613K	0.01%	1040
2019 Q4	–	Sell	-12,847	Closed	-$1.9M	–	1502
2019 Q3	$1.9M	Buy	+12,847	New	+$1.43M	0.06%	321

Other funds holding VRCA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Conning Inc Hartford, Connecticut $3.01B AUM 16.23% 1-Year Est. Return

Schonfeld Strategic Advisors's VRCA Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q4 2022, closing a stake of 1,340 shares — an estimated $39K sold.

Schonfeld Strategic Advisors first reported a position in VRCA in Q3 2019 and held it in 4 quarters. The position peaked at $1.9M in Q3 2019. 50 funds tracked by Wall St. Rank hold VRCA as of Q4 2022.

Schonfeld Strategic Advisors reported no remaining Verrica Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 1,340 Verrica Pharmaceuticals shares in Q4 2022, an estimated $39K.
Schonfeld Strategic Advisors first reported a position in Verrica Pharmaceuticals in Q3 2019 and held it in 4 quarters.
Schonfeld Strategic Advisors's Verrica Pharmaceuticals position peaked at $1.9M in Q3 2019.
50 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.